All participants will be awarded a certificate of completion for self-reporting to other colleges
Duration: 30 minutes
Treatment of MOH may be difficult, and so it is important for patients to understand how to prevent this condition in the first place. As a healthcare professional, learn how to recognise patients at risk of MOH and educate them on how to avoid falling into the cyclical trap of overusing their headache medications.
Upon completing this course, participants will be able to:
List the classes of medications used to prevent chronic migraine;
Differentiate treatment for infrequent severe headaches and frequent episodic headaches;
Outline a plan to address the most common barriers to managing MOH and codeine-withdrawal effects;
Explain the interdisciplinary (between GPs and pharmacists) management of MOH;
Put a reminder system in place that would make use of the different monitoring strategies (e.g. headache diaries, support from both GPs and pharmacists, use of clinical measures of headache-related disability) to assess patient compliance to preventive treatment.
Associate Professor Richard Stark: Co-authored a clinical paper sponsored by Pfizer on the safety of eletriptan. Between 2012 and 2014 received consulting and lecture fees from Allergan and lecture fees from MSD on chronic migraine
Professor Mieke Van Driel: No conflict of interest
Associate Professor Treasure McGuire: No conflict of interest
Dr Brett McFarlane: No conflict of interest
Professor Deborah Turnbull: Received research grants and co-authored papers on hypertension sponsored by pharmaceutical companies, including Pfizer Pty. Ltd., between 1999 and 2006
Dr Lara Mihaljevic: No conflict of interest
Non-faculty: employees of In Vivo Academy involved in producing the content of this course, Aishwarya Sridharan, Tina Garcia, Monica Kurniawan and Lisa Sullivan, declare no conflict of interest.